/PRNewswire/ The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, announced today that AbbVie.
AbbVie to maintain exclusive access to Calibr-Skaggs switchable CAR-T platform to develop novel cell therapy candidates against solid tumor targets identified by AbbVieAbbVie also has the option.